Post Reply
4141-4160 of 10899
Heng ah, not me. No hurry. Kindly, can share, wat is your profit margin level, ie 1%-100%, as AK dun hv any level for ref, still blur blur loh. On d other hand, can also share your comfortable cut loss margin as well? Or other means of prudent cut loss n profit taking stretegy? Ha ha, above r million dollar's Qn, lengthy explanation is needed, if that so, kindly discard them. AK will slowly learn fr d sifus fr d forum. Anyway, tks for your promt advice.
PS. Dr Tan had shed some lights on stock investment on today's Zaobao BUSINESS, page 25.
crimson ( Date: 19-Jan-2010 09:37) Posted:
| wahahaha... fast up fast down... the moment hit resistance everyone just short it down... all taking profit liao... and the cycle begins |
|
wahahaha... fast up fast down... the moment hit resistance everyone just short it down... all taking profit liao... and the cycle begins
Based on Fib retracement, if BIG breaks the 0.90 resistance I think the $1.12 level will go quickly.
any near term TP?
A very farsighted sifu. Tks for d prompting n advice. Cheers.
crimson ( Date: 18-Jan-2010 16:54) Posted:
|
about to test the resistance now!!! go BIG
dinola ( Date: 18-Jan-2010 12:08) Posted:
| With this news, is the statement below still valid |
|
|
|
about to test the resistance now!!! go BIG
dinola ( Date: 18-Jan-2010 12:08) Posted:
With this news, is the statement below still valid?
gbleng ( Date: 04-Jan-2010 10:08) Posted:
| Next resistance 0.90..... after that > 1.12 |
|
|
|
With this news, is the statement below still valid?
gbleng ( Date: 04-Jan-2010 10:08) Posted:
| Next resistance 0.90..... after that > 1.12 |
|
wahahaha chiong liao ah!!!
Ha ha, dear comrade, wat a facinating news on DES. In time to come, more such good news will be shining on ds baby. D coming result would definitely add on more colour liao.
But apa da, today's Zaobao, main page 04, one of d local heart related illness consultants stressed that surgeon had over used of DES, esp those in private hosp, instead of d half d px cheaper of Bare Metal Stent, BMS, and hv about d same reliability.
If China finally also following d footstep of France, really AK must say words which I never use in d forum, Huat Ahhhhhhhhh...... Cheers for sifus for their invaluable advice sometime ago, n d supporters.
Singapore, 18 January 2010
announced today that its BioMatrix™ drug
– Biosensors International Group, Ltd. (“Biosensors”, Bloomberg: BIG SP)-eluting stent system has received approval for
reimbursement in France. The addition of BioMatrix to the LPPR (“Liste des Produits et Prestations
Remboursables”) was published in the Journal Official on 15 January 2010 and a
announcement, the BioMatrix will be available from 28 January 2010 to patients with coronary artery
disease throughout France
s a result of this.
Mr. Mike Kleine, President & CEO said, “We are very pleased to have obtained reimbursement in
France. French authorities have a particularly rigorous review process and will only grant
reimbursement to a product which can clearly demonstrate both clinical and economic benefits. For us
this is additional recognition of the robust body of clinical evidence that supports our innovative
technology.”
“France is the largest market for drug
This approval further demonstrates our ability to address various regulatory approval processes across
the world as we introduce our technology globally. France represents a tremendous market
-eluting stents in Europe, and one of the largest in the world.
opportunity for Biosensors,” concluded Mr. Kleine
.
BioMatrix™ was launched in all other major European markets in April 2008, where its unique
combination of Biosensors-developed abluminal biodegradable polymer and proprietary limus drug,
Biolimus A9
™, rapidly proved successful. BioMatrix’s introduction has also generated very positive
feedback in other parts of the world, such as Asia and Latin America.
"BIG"CHEONG!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!AR!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
My apologies - Just went to listen to the audio conference again.
THe 1.6Billion dollars valuation that the CEO was talking about was for a chinese company that has just been listed, in the same health-related sector as JWMS, and of a similar size.
So, the CEO is saying that if this chinese company can fetch this valuation, why not JWMS.
On another point, the CEO mentioned that the company is pursuing addtional STRATEGIC relationships to accelerate growth opportunites, and this specifically involves their strategy in the US mkt.
For info.
Comrade, thats a very encouraging prospect on BIG, esp 3Q result about to be tabled soon.
Be it USD 0.45 n 0.80 for S$0.62 n 1.11 respectively, happy liao.
OK, will still hold ds burger, see it can climb near a S$, as some sifus posted earlier. Tks for all d sifus n supporters. Cheers.
investor ( Date: 16-Jan-2010 00:23) Posted:
In the JP Morgan health conference, Biosensors' CEO Mike Kleine mentioned for the first time ever (they have never talk about Terumo's Japan contract), that if Terumo gets the approval to mkt the Bio-matrix in Japan, it will greatly enhance the profitability of Biosensors, and that the licencing will be for 5 yrs starting from the date of approval.
Also, He mentioned that the JWMS (JW Medical) in China, of which Biosensors owned 50 % is greatly undervalued, and that if they compare it to other listed chinese companies in China stock exchange, it is probably worth $1.6 billion (I think that I heard it as that figure - anybody has tuned into the audio conf, kindly verfiy this).
This figure is probably in US$, and if it is true, then it is worth about US$0.80 per share to Biosensors. (assuming that Biosensors has about 1 billion shares).
My own opinion is that JWMS has annualised net profit of US$30m per yr, and if you take a PE ratio of 30 times as reasonable, then JWMS is worth about US$900m, or about US$0.45 per share to Biosensors.
THe above are mere conjectures on my part - take it with a pinch of salt. FOr more accurate details, kindly go and listen to the video conference. at https://events.jpmorgan.com/
Not a call to buy/sell.
|
|
In the JP Morgan health conference, Biosensors' CEO Mike Kleine mentioned for the first time ever (they have never talk about Terumo's Japan contract), that if Terumo gets the approval to mkt the Bio-matrix in Japan, it will greatly enhance the profitability of Biosensors, and that the licencing will be for 5 yrs starting from the date of approval.
Also, He mentioned that the JWMS (JW Medical) in China, of which Biosensors owned 50 % is greatly undervalued, and that if they compare it to other listed chinese companies in China stock exchange, it is probably worth $1.6 billion (I think that I heard it as that figure - anybody has tuned into the audio conf, kindly verfiy this).
This figure is probably in US$, and if it is true, then it is worth about US$0.80 per share to Biosensors. (assuming that Biosensors has about 1 billion shares).
My own opinion is that JWMS has annualised net profit of US$30m per yr, and if you take a PE ratio of 30 times as reasonable, then JWMS is worth about US$900m, or about US$0.45 per share to Biosensors.
THe above are mere conjectures on my part - take it with a pinch of salt. FOr more accurate details, kindly go and listen to the video conference. at
https://events.jpmorgan.com/
Not a call to buy/sell.
different from the past..usually middle of feb and after market closed. Btw Terumo reporting results on
28/01/2010 night....something might be up.....just my speculation.
DATE OF ANNOUNCEMENT OF FINANCIAL RESULTS FOR THIRD QUARTER OF
FISCAL YEAR 2010 ENDED 31 DECEMBER 2009
Biosensors International Group, Ltd. (“Biosensors” or the “Company”) will announce its
financial results for the third quarter of its fiscal year 2010, ended 31 December 2009 on 29
January 2010, before trading hours.
Mr. Mike Kleine, President & CEO and Mr. Kevin Sayer, CFO will host an analyst briefing
teleconference on that day at 7.15 am (Singapore time) to discuss the financial results and
provide an update on the Company’s progress.
A live audio-cast of the briefing will be available to all interested parties at Biosensors’
corporate website at www.biosensors.com.
Ha ha, forcing to 0.835 n probably shoot ax it as strong blocking at 0.83.
AK opines that, taking reference to its 1H10 sound finance report n other future undertakings, optimism at d investors bound to be there.
Those who got it below 0.60 hoe shei liao, or even below 0.75. Cheers for all d supporters.
wow ! someone one mouth gulped 500 lots.
BIG just got approval from Korea, France's approval before end of March.
In the website CRTONLINE.org, there is a video showing Dr. Alexandre Abizaid being interviewed.
THe topic of conversation was the Biosensors' polymer-free DES, called the bio-freedom.
The 4-mth clinical results showed a late loss of 0.07, 0.17, and 0.38 for the bio-freedom, std dose, lower dose and taxus liberte control respectively.
THe body language, positive tone of Dr. Alexandre on the results augurs well for this technology, and he mentioned about the 12-mths results, which will probably be released in May this yr, in EuroPCR.
HE mentioned that the healing ( that is the formation of hperplasia on the stent) was very even, millimetre by millimetre.
My interpretation of this interview, as well as the interview of Dr. Philip Urban (another video conf), is that the general trend and thinking of leading researchers, is that biodegradable polymer and no-polymer is the way forward, until such time that technology can produce a bio-degradable stent.
It will be interesting to see, whether this trend in thinking among researchers filter down to the general DES practitioners, who generally are still using the durable polmyer based DES. (maybe because of the mkting power of the big players like Abbot, Medtronic, etc).
For info. Not a call to buy/sell
It's time to test the resistance at $0.91. Biosensor is a good share to vest as it's in niche industry where not many competitors are around. When the market pick up, it'll cheong all the way.
